Conferences - Results from #11400

GU Cancers Symposium 2013 - Effect of PSA-TRICOM, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa, by James L. Gulley, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study, by Robert van Soest, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis, by Jessica Strock, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer, by Bertrand Tombal, MD, PhD, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in patients with biochemically-recurrent prostate cancer, by Emmanuel S. Antonarakis, MD, et al. - Session Highlights February 23, 2013

GU Cancers Symposium 2013 - Serum IGF-1 levels are decreased in men with advanced prostate cancer treated with the ERα agonist, GTx-758, by Evan Y. Yu, MD, et al. - Poster February 22, 2013

GU Cancers Symposium 2013 - Variations in treatment modality use for the definitive management of prostate cancer in the United States, by Jay P. Ciezki, MD , et al. - Poster February 22, 2013

GU Cancers Symposium 2013 - Variations in treatment modality use for the definitive management of prostate cancer in the United States, by Jay P. Ciezki, MD , et al. - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Stereotactic body radiation (SBRT) following procedures for benign prostatic hyperplasia (BPH): A report of early toxicity, by Marie Kate Gurka, MD, et al. - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase 3 study of abiraterone acetate in metastatic castration-resistant prostate cancer, by Oscar B. Goodman Jr., MD, PhD, et al. - Poster February 21, 2013

GU Cancers Symposium 2013 - High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study, by Abdenour Nabid, MD, et al. - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Session Highlights February 20, 2013

GU Cancers Symposium 2013 - Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) February 20, 2013

GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Podcast February 20, 2013

GU Cancers Symposium 2013 - Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer, by Matthew R. Cooperberg, MD, MPH, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - Open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer patients previously treated with sipuleucel-T: Evaluation of androgen-presenting cell activation, by L. Michael Glode, MD, et al. February 20, 2013

GU Cancers Symposium 2013 - Utilization of cancer detection by U.S. prostate biospies (2005-2011), by Carl A. Olsson, MD, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - Radical or partial nephrectomy for localized disease in elderly patients? by Alexander Kutikov, MD - Session Highlights February 20, 2013

Page 571 of 594